Journal article
Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic
M Schmitz, E Ebert, K Stoeck, A Karch, S Collins, M Calero, T Sklaviadis, JL Laplanche, E Golanska, I Baldeiras, K Satoh, R Sanchez-Valle, A Ladogana, A Skinningsrud, AL Hammarin, E Mitrova, F Llorens, YS Kim, A Green, I Zerr
Molecular Neurobiology | SPRINGER | Published : 2016
Abstract
At present, the testing of 14-3-3 protein in cerebrospinal fluid (CSF) is a standard biomarker test in suspected sporadic Creutzfeldt-Jakob disease (sCJD) diagnosis. Increasing 14-3-3 test referrals in CJD reference laboratories in the last years have led to an urgent need to improve established 14-3-3 test methods. The main result of our study was the validation of a commercially available 14-3-3 ELISA next to the commonly used Western blot method as a high-throughput screening test. Hereby, 14-3-3 protein expression was quantitatively analyzed in CSF of 231 sCJD and 2035 control patients. We obtained excellent sensitivity/specificity values of 88 and 96 % that are comparable to the establi..
View full abstractGrants
Awarded by EU Joint Programme – Neurodegenerative Disease Research
Funding Acknowledgements
The study was performed within the recently established Clinical Dementia Center at the University Medical Center Gottingen and was supported by grants from the EU Joint Program Neurodegenerative Disease Research [JPND-DEMTEST (Biomarker based diagnosis of rapid progressive dementias-optimization of diagnostic protocols, 01ED1201A)]. This study was also partly supported by the Robert Koch Institute through funds from the Federal Ministry of Health (grant no. 1369-341) and by a grant from the European Commission (Protecting the food chain from prions: shaping European priorities through basic and applied research (PRIORITY, No. 222887) Project number: FP7-KBBE-2007-2A). Thanks to Michele Equestre for technical assistance. The Australian National CJD Registry is funded by the Commonwealth Department of Health and S Collins is supported by a NHMRC Practitioner Fellowship (#APP1005816).